ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer.
Ontology highlight
ABSTRACT: A subset of lung cancers is dependent on the anaplastic lymphoma kinase (ALK) oncogene for survival, a mechanism that is exploited by the use of the ALK inhibitor crizotinib. Despite exceptional initial tumor responses to ALK inhibition by crizotinib, durable clinical response is limited and the emergence of drug resistance occurs. Furthermore, intrinsic resistance is frequently observed, where patients fail to respond initially to ALK-inhibitor therapy. These events demonstrate the underlying complexity of a molecularly-defined oncogene-driven cancer and highlights the need to identify compensating survival pathways. Using a loss-of-function whole genome short-hairpin (shRNA) screen, we identified MYCBP as a determinant of response to crizotinib, implicating the MYC signaling axis
SUBMITTER: Pilling AB
PROVIDER: S-EPMC5823650 | biostudies-literature | 2018 Feb
REPOSITORIES: biostudies-literature
ACCESS DATA